Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, institute physician, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses preliminary data from a phase 2 study (NCT05065554) of acalabrutinib (Calquence) plus rituximab (Rituxan) in patients with Waldenström’s Macroglobulinemia or IgM symptomatic anti-myelin associated glycoprotein (MAG)–mediated peripheral neuropathy.

Please note this trial is still recruiting patients: